New Translational Research in the Medical Management of Orbital Melanoma

REFERENCES

• Shields JA, Shields CL. Orbital malignant melanoma: The 2002 Sean B Murphy lecture. Ophthal Plast Reconstr Surg 2003;19(4):262–269
   PubMed Web of Science ®Google Scholar
• Liarikos S, Rapidis AD, Roumeliotis A, Angelopoulos AP. Secondary orbital melanomas: Analysis of 15 cases. J Craniomaxillofac Surg 2000;28(3):148–152
   PubMed Web of Science ®Google Scholar
• Polito E, Leccisotti A. Primary and secondary orbital melanomas: A clinical and prognostic study. Ophthal Plast Reconstr Surg 1995;11(3):169–181
   PubMed Web of Science ®Google Scholar
• Ke Y, Ren X, Zhu L, et al. Primary orbital melanoma combined with giant divided nevus of the eyelid. J Craniofac Surg 2014;25(1):e4–e7
   PubMed Web of Science ®Google Scholar
• Radhadevi C V, Charles KS, Lathika VK. Orbital malignant melanoma associated with nevus of Ota. Indian J Ophthalmol 2013;61(6):306–309
   PubMed Web of Science ®Google Scholar
• Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 2012;59(1):121–125
   PubMed Web of Science ®Google Scholar
• Orcutt JC, Char DH. Melanoma metastatic to the orbit. Ophthalmology 1988;95(8):1033–1037
   PubMed Web of Science ®Google Scholar
• Kuo C-H, Gao K, Clifford A, et al. Orbital exenterations: An 18-year experience from a single head and neck unit. ANZ J Surg 2011;81(5):326–330
   PubMed Web of Science ®Google Scholar
• Wong JCL, Thampy R, Cook A. Life expectancy following orbital exenteration. Br J Ophthalmol 2015;99(1):1–4
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN Clinical Practice Guidelines Oncology Melanoma. 2015. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
   Google Scholar
• Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25(34):5426–5434
   PubMed Web of Science ®Google Scholar
• Hodis E, Watson IR, Kryukov G V, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251–263
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711–723
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517–2526
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012;13(5):459–465
   PubMed Web of Science ®Google Scholar
• Long G V, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239–1246
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707–714
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809–819
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507–2516
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients iwth BRAF V600E-mutated melanoma. Presentation at the ASCO Annual Meeting, 2012. Available online at http://meetinglibrary.asco.org/content/96291-114 . Last accessed December 2, 2015
   Google Scholar
• Long G V, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087–1095
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107–114
   PubMed Web of Science ®Google Scholar
• Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 2012;9(3):241–247
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–2454
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134–144
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568–571
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384(9948):1109–1117
   PubMed Web of Science ®Google Scholar
• Robert C, Long G V, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014;372:320–330
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32(10):1020–1030
   PubMed Web of Science ®Google Scholar
• Weber J, Minor D, D’Angelo S, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma with prior anti-CTLA-4 therapy. Presented to European Society for Medical Oncology, Madrid, Spain, September 2014
   Google Scholar
• Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31(4):482–489
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694–1703
   PubMed Web of Science ®Google Scholar
• Kefford R, Miller, W. H. J, Tan D, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. Presented to American Society of Clinical Oncology, Chicago, IL, June 2013
   Google Scholar
• Long G V, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371(20):1877–1888
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371(20):1867–1876
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):320–330
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122–133
   PubMed Web of Science ®Google Scholar
• Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014;120(11):1695–1701
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sileni VC, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014;32(4):144–149
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29(21):2904–2909
   PubMed Web of Science ®Google Scholar